Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 6/20 | 0.96 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.55 |
| ▸ | SCN1A known ✓ | P35498 | 2/20 | 0.49 |
| ▸ | SCN2A known ✓ | Q99250 | 2/20 | 0.49 |
| ▸ | SCN3A known ✓ | Q9NY46 | 2/20 | 0.49 |
| ▸ | HCRTR1 known ✓ | O43613 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.96 |
| ▸ | CA9 | Q16790 | 5/20 | 0.96 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8125684 | 0.98 | CA2 (0.92) | CA2CA1CA9CDK2F2 | |
| SCHEMBL28464 | 0.98 | CA2 (1.00) | CA2CA1CA9CDK2F2 | |
| SCHEMBL29529240 | 0.98 | CA2 (1.00) | CA2CA1CA9CDK2F2 | |
| SCHEMBL27901054 | 0.96 | CA2 (0.96) | CA2CA1CA9CDK2F2 | |
| Ammonia Solution, Strong SCHEMBL28028391 | 0.96 | CA2 (0.96) | CA2CA1CA9CDK2F2 | |
| Benzene SCHEMBL11062753 | 0.96 | CA2 (0.96) | CA2CA1CA9CDK2F2 | |
| Phosphoric Acid SCHEMBL28841729 | 0.88 | CA2 (0.81) | CA2CA1CA9CDK2F2 | |
| Isothiocyanate SCHEMBL28619475 | 0.87 | CA2 (0.79) | CA2CA1CA9CDK2F2 | |
| Acetamide SCHEMBL28617889 | 0.87 | CA2 (0.79) | CA2CA1CA9CDK2F2 | |
| SCHEMBL3149642 | 0.86 | CA2 (0.78) | CA2CA1CA9CDK2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9533069-B2 | Device for promotion of hemostasis and/or wound healing | Ferrosan Medical Devices A/S (DK) | 2017-01-03 | — | — | US | disclosed |
| US-20140220130-A1 | Device For Promotion Of Hemostasis And/or Wound Healing | Ferrosan Medical Devices A/S (DK) | 2014-08-07 | — | — | US | disclosed |
| US-8642831-B2 | Device for promotion of hemostasis and/or wound healing | Ferrosan Medical Devices A/S (DK) | 2014-02-04 | — | — | US | disclosed |
| US-20130029030-A1 | METHOD FOR PROMOTION OF HEMOSTASIS AND/OR WOUND HEALING | Ferrosan Medical Devices A/S (DK) | 2013-01-31 | — | — | US | disclosed |
| CN-101812063-B | Alpha-naphthalenesulfonamide five-membered heterocyclic compound and tumor inhibition activity thereof | INST OF MEDICINAL BIOTECHNOLOGY ACADEMY OF MEDICAL SCIENCES | 2012-04-25 | — | — | CN | disclosed |
| US-20110021964-A1 | Device for Promotion of Hemostasis and/or Wound Healing | Ferrosan Medical Devices A/S (DK) | 2011-01-27 | — | — | US | disclosed |
| CN-101812063-A | Alpha-naphthalenesulfonamide base quintuple heterocyclic compound and anti-tumor activity thereof | INST MED BIOTECHNOLOGY CAMS | 2010-08-25 | — | — | CN | disclosed |
| WO-2009131654-A2 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2009-10-29 | — | — | WO | disclosed |
| CN-100441180-C | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2008-12-10 | — | — | CN | disclosed |
| CN-1271052-C | Sulfonamide derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2006-08-23 | — | — | CN | disclosed |
| CN-1816334-A | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2006-08-09 | — | — | CN | disclosed |
| CN-1599718-A | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | ESTEVE LABOR DR (ES) | 2005-03-23 | — | — | CN | disclosed |
| CN-1561338-A | Chroman derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2005-01-05 | — | — | CN | disclosed |